Harold John Burstein MD

Breast Cancer, Hematologic Oncology

Associate Professor of Medicine, Dana-Farber Cancer Institute

44 Binney St# DanaBoston, MA 02115
Phone+1 617-632-2624
Fax+1 617-632-1930

Dr. Burstein is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burstein's full profile Already have an account?

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1999
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1994 - 1996
Harvard Medical SchoolClass of 1994

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
RI State Medical License 2022 - 2028
CT State Medical License 2022 - 2027
MA State Medical License 1996 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 2 Certification EpicCare Inpatient 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2015, 2017
CMS Meaningful Use Stage 1 Certification Partners Longitudinal Medical Record, Partners Healthcare System, 2012, 2014-2015, 2017

Clinical Trials

Rebeccamycin Analogue in Treating Women With Stage IIIB or Stage IV Breast Cancer
COMPLETED
PHASE2
Bevacizumab Plus Vinorelbine in Treating Patients With Stage IV Breast Cancer
COMPLETED
PHASE2
Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer
COMPLETED
PHASE1, PHASE2

Publications & Presentations

PubMed

Now or later? Switching therapies in metastatic breast cancer.
Carmine Valenza, Meredith M Regan, Harold J Burstein
The Lancet. Oncology. 2026-08-01
Progression-Free Survival in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review: A Systematic Review and Meta-Analysis.
Lis Victoria Ravani, Zahra Bagheri, Kevin Kalinsky, Harold J Burstein, Aditya Bardia
JAMA Oncology. 2026-07-16
Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology.
William J Gradishar, Meena S Moran, Jame Abraham, Vandana Abramson, Rebecca Aft
Journal of the National Comprehensive Cancer Network. 2026-07-01

Journal Articles

Adjuvant Capecitabine in Triple-Negative Breast Cancer
Harold Burstein, MD, JAMA
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer
Aminah Jatoi, Antonio C Wolff, Harvey Jay Cohen, Rachel A Freedman, Gustav Magrinat, Julie Gralow, Gretchen Kimmick, Heidi D Klepin, Harold Burstein, Hyman Muss, Jeann..., Journal of the American Geriatrics Society

Lectures

Genomic Profiling in ER-Positive Breast Cancer, From MINDACT to TAILORx
ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
Breast Cancer, New Horizons, Current Controversies
Harvard Medical School, Boston, Massachusetts - 7/11/2013
The New York Metropolitan Breast Cancer Group 40th Annual Symposium: Breast Cancer 2013
The New York Academy of Medicine, New York, New York - 2/2/2013

Press Mentions

Adding Tucatinib to First-Line Maintenance Therapy Improves PFS in HER2+ Metastatic Breast CancerDecember 11th, 2025
What to Watch for at the 2025 San Antonio Breast Cancer SymposiumDecember 3rd, 2025
Radiation May Be Unnecessary for Many Breast Cancer PatientsNovember 6th, 2025